

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 1999 MONTANA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE 8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE 9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NF RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NF RESIDENTS, BY TOP 10 DRUG GROUP

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE 11. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 12. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 13. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 14. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 15. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 16-16D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE 17. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE 18. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NF RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS

TABLE 11

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | No. of Benefes | | | | | | | No. of Bene Mos | | | | | | | | | | | |
|---|----------------|--------------|--------------|------------|----------|-------------------|----------------|-----------------|---------------|--------------|-----------|-------------------|----------------|---------------|---------------|--------------|-----------|-------------------|---|
| | All | Aged | Disabled | Adults | Children | Other/ Unknown | All | Aged | Disabled | Adults | Children | Other/ Unknown | All | Aged | Disabled | Adults | Children | Other/ Unknown | |
| All | 16,378 | 9,030 | 6,724 | 622 | 2 | 0 | 158,165 | 83,967 | 67,025 | 7,149 | 24 | 0 | 158,165 | 83,967 | 67,025 | 7,149 | 24 | 0 | |
| Age | | | | | | | | | | | | | | | | | | | |
| 5 and younger | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-14 | 5 | 0 | 4 | 0 | 1 | 0 | | 0 | 45 | 0 | 12 | 0 | | 0 | 45 | 0 | 12 | 0 | 0 |
| 15-20 | 22 | 0 | 21 | 0 | 1 | 0 | | 236 | 224 | 0 | 12 | 0 | | 224 | 0 | 0 | 12 | 0 | 0 |
| 21-44 | 3,032 | 5 | 2,731 | 296 | 0 | 0 | | 31,544 | 28,150 | 3,334 | 0 | 0 | | 28,150 | 3,334 | 0 | 0 | 0 | 0 |
| 45-64 | 3,406 | 8 | 3,145 | 253 | 0 | 0 | | 33,116 | 30,059 | 2,961 | 0 | 0 | | 30,059 | 2,961 | 0 | 0 | 0 | 0 |
| 65-74 | 3,349 | 2,640 | 664 | 45 | 0 | 0 | | 31,620 | 6,837 | 518 | 0 | 0 | | 24,265 | 6,837 | 518 | 0 | 0 | 0 |
| 75-84 | 3,335 | 3,184 | 129 | 22 | 0 | 0 | | 30,956 | 1,383 | 264 | 0 | 0 | | 29,309 | 1,383 | 264 | 0 | 0 | 0 |
| 85 and older | 3,229 | 3,193 | 30 | 6 | 0 | 0 | | 30,636 | 327 | 72 | 0 | 0 | | 30,237 | 327 | 72 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | | | | | | | | |
| Female | 10,489 | 6,614 | 3,582 | 293 | 0 | 0 | | 103,427 | 36,857 | 3,359 | 0 | 0 | | 63,211 | 36,857 | 3,359 | 0 | 0 | 0 |
| Male | 5,889 | 2,416 | 3,142 | 329 | 2 | 0 | | 54,738 | 30,168 | 3,790 | 24 | 0 | | 20,756 | 30,168 | 3,790 | 24 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | | | | | | | | |
| White | 14,842 | 8,342 | 5,931 | 568 | 1 | 0 | | 142,350 | 58,723 | 6,555 | 12 | 0 | | 77,060 | 58,723 | 6,555 | 12 | 0 | 0 |
| African American | 47 | 20 | 27 | 0 | 0 | 0 | | 392 | 205 | 0 | 0 | 0 | | 187 | 205 | 0 | 0 | 0 | 0 |
| Other/unknown | 1,489 | 668 | 766 | 54 | 1 | 0 | | 15,423 | 8,097 | 594 | 12 | 0 | | 6,720 | 8,097 | 594 | 12 | 0 | 0 |
| Use of Nursing Facilities | | | | | | | | | | | | | | | | | | | |
| All year | 3,526 | 3,233 | 291 | 2 | 0 | 0 | | 35,280 | 3,199 | 24 | 0 | 0 | | 32,057 | 3,199 | 24 | 0 | 0 | 0 |
| Part year | 1,379 | 1,205 | 162 | 12 | 0 | 0 | | 11,570 | 1,522 | 141 | 0 | 0 | | 9,907 | 1,522 | 141 | 0 | 0 | 0 |
| None | 11,473 | 4,592 | 6,271 | 608 | 2 | 0 | | 111,315 | 62,304 | 6,984 | 24 | 0 | | 42,003 | 62,304 | 6,984 | 24 | 0 | 0 |
| Maintenance Assistance Status | | | | | | | | | | | | | | | | | | | |
| Cash | 6,009 | 1,942 | 4,044 | 22 | 1 | 0 | | 65,406 | 43,730 | 212 | 12 | 0 | | 21,452 | 43,730 | 212 | 12 | 0 | 0 |
| Medically needy | 7,623 | 5,663 | 1,960 | 0 | 0 | 0 | | 64,065 | 15,638 | 0 | 0 | 0 | | 48,427 | 15,638 | 0 | 0 | 0 | 0 |
| Poverty-related | 7 | 0 | 0 | 7 | 0 | 0 | | 35 | 0 | 35 | 0 | 0 | | 0 | 0 | 35 | 0 | 0 | 0 |
| Other/unknown | 2,739 | 1,425 | 720 | 593 | 1 | 0 | | 28,659 | 7,657 | 6,902 | 12 | 0 | | 14,088 | 7,657 | 6,902 | 12 | 0 | 0 |
| Dual Medicare Status^c | | | | | | | | | | | | | | | | | | | |
| Full dual, all year | 16,378 | 9,030 | 6,724 | 622 | 2 | 0 | | 158,165 | 83,967 | 7,149 | 24 | 0 | | 83,967 | 67,025 | 7,149 | 24 | 0 | 0 |
| Full dual, part year | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 |
| Managed Care Status | | | | | | | | | | | | | | | | | | | |
| FFS all year | 16,359 | 9,030 | 6,713 | 614 | 2 | 0 | | 158,040 | 66,943 | 7,106 | 24 | 0 | | 83,967 | 66,943 | 7,106 | 24 | 0 | 0 |
| FFS part year, with Rx claims | 17 | 0 | 10 | 7 | 0 | 0 | | 119 | 77 | 42 | 0 | 0 | | 0 | 77 | 42 | 0 | 0 | 0 |
| FFS part year, no Rx claims | 2 | 0 | 1 | 1 | 0 | 0 | | 6 | 5 | 1 | 0 | 0 | | 0 | 5 | 1 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table 11 includes the beneficiaries represented by Cells G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

Table 11

Dual Eligible Beneficiaries

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 1999. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE 12
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BENEFICIARY CHARACTERISTIC^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | % with at Least One Rx | Mean No. of Rx | Mean Rx \$ | \$ per Rx | Mean \$, All Services | Rx \$ as % of All Services | Mean OTC Drug \$ ^c | No. of Benef |
|--------------------------------------|------------------------|----------------|------------|-----------|-----------------------|----------------------------|-------------------------------|--------------|
| All | 86.1 % | 41.2 | \$1,740 | \$42 | \$11,043 | 15.8 % | \$25 | 16,378 |
| Age | | | | | | | | |
| 5 and younger | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 | 0 |
| 6-14 | 80.0 | 39.6 | 2,833 | 72 | 13,652 | 20.8 | 2 | 5 |
| 15-20 | 77.3 | 28.6 | 2,138 | 75 | 14,338 | 14.9 | 1 | 22 |
| 21-44 | 83.8 | 31.1 | 2,034 | 65 | 7,261 | 28.0 | 21 | 3,032 |
| 45-64 | 85.5 | 43.7 | 2,170 | 50 | 8,900 | 24.4 | 34 | 3,406 |
| 65-74 | 80.1 | 38.6 | 1,466 | 38 | 7,767 | 18.9 | 29 | 3,349 |
| 75-84 | 88.2 | 45.3 | 1,586 | 35 | 12,884 | 12.3 | 26 | 3,335 |
| 85 and older | 93.1 | 46.8 | 1,448 | 31 | 18,324 | 7.9 | 14 | 3,229 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 | 0 |
| Basis of Eligibility | | | | | | | | |
| Aged | 87.9 | 44.1 | 1,513 | 34 | 13,494 | 11.2 | 23 | 9,030 |
| Disabled | 82.9 | 37.5 | 2,024 | 54 | 8,181 | 24.7 | 27 | 6,724 |
| Adults | 94.5 | 40.2 | 1,959 | 49 | 6,420 | 30.5 | 32 | 622 |
| Children | 50.0 | 11.5 | 1,056 | 92 | 4,064 | 26.0 | 0 | 2 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 | 0 |
| Gender | | | | | | | | |
| Female | 89.6 | 46.6 | 1,860 | 40 | 11,756 | 15.8 | 27 | 10,489 |
| Male | 79.9 | 31.6 | 1,526 | 48 | 9,772 | 15.6 | 21 | 5,889 |
| Unknown | 0.0 | 0.0 | 0 | 0 | 0 | 0.0 | 0 | 0 |
| Race | | | | | | | | |
| White | 88.2 | 43.0 | 1,811 | 42 | 11,309 | 16.0 | 25 | 14,842 |
| African American | 83.0 | 33.2 | 2,131 | 64 | 10,059 | 21.2 | 33 | 47 |
| Other/unknown | 64.8 | 23.8 | 1,016 | 43 | 8,418 | 12.1 | 25 | 1,489 |
| Use of Nursing Facilities | | | | | | | | |
| Entire year | 94.7 | 56.9 | 1,902 | 33 | 24,480 | 7.8 | 24 | 3,526 |
| Part year | 94.5 | 48.6 | 1,720 | 35 | 15,340 | 11.2 | 23 | 1,379 |
| None | 82.4 | 35.5 | 1,692 | 48 | 6,397 | 26.5 | 26 | 11,473 |
| Maintenance Assistance Status | | | | | | | | |
| Cash | 80.9 | 32.7 | 1,521 | 47 | 4,455 | 34.1 | 22 | 6,009 |
| Medically needy | 88.2 | 45.9 | 1,829 | 40 | 14,361 | 12.7 | 25 | 7,623 |
| Poverty related | 85.7 | 5.7 | 176 | 31 | 1,116 | 15.7 | 0 | 7 |
| Other/unknown | 91.6 | 46.9 | 1,976 | 42 | 16,284 | 12.1 | 30 | 2,739 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

Table 12

Dual Eligible Beneficiaries

a. Table 12 includes beneficiaries represented by Cell G of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Information about OTC drugs appears in this column only. OTC drugs are not part of the reimbursement amount for prescription drugs.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 13
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | Mean No. of Rx | Mean Rx \$ | Rx \$ as % of All Services | No. of Rx, % with: | | | | | Mean \$, All Services | Benes | Bene Mos | |
|--------------------------------------|----------------|------------|----------------------------|--------------------|----------------------------|----------------------------|----------------------------|-----------------------------|-----------------------|---------|----------|--------------|
| | | | | None | More than 0, but 1 or Less | More than 1, but 2 or Less | More than 2, but 5 or Less | More than 5, but 10 or Less | | | | More than 10 |
| All | 4.3 | \$180 | 15.8 % | 13.9 % | 17.5 % | 10.7 % | 28.0 % | 23.0 % | 6.8 % | \$1,144 | 16,378 | 158,165 |
| Age | | | | | | | | | | | | |
| 5 and younger | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| 6-14 | 3.5 | 249 | 20.8 | 20.0 | 0.0 | 0.0 | 60.0 | 20.0 | 0.0 | 1,198 | 5 | 57 |
| 15-20 | 2.7 | 199 | 14.9 | 22.7 | 27.3 | 13.6 | 13.6 | 22.7 | 0.0 | 1,337 | 22 | 236 |
| 21-44 | 3.0 | 196 | 28.0 | 16.2 | 29.8 | 13.2 | 23.8 | 13.2 | 3.8 | 698 | 3,032 | 31,544 |
| 45-64 | 4.5 | 223 | 24.4 | 14.5 | 17.2 | 10.4 | 27.5 | 22.5 | 7.8 | 915 | 3,406 | 33,116 |
| 65-74 | 4.1 | 155 | 18.9 | 19.9 | 16.7 | 10.4 | 25.3 | 21.1 | 6.6 | 823 | 3,349 | 31,620 |
| 75-84 | 4.9 | 171 | 12.3 | 11.8 | 13.4 | 9.2 | 29.8 | 27.4 | 8.2 | 1,388 | 3,335 | 30,956 |
| 85 and older | 4.9 | 153 | 7.9 | 6.9 | 11.5 | 10.6 | 33.5 | 30.2 | 7.3 | 1,931 | 3,229 | 30,636 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Basis of Eligibility | | | | | | | | | | | | |
| Aged | 4.7 | 163 | 11.2 | 12.1 | 13.7 | 10.1 | 29.7 | 26.7 | 7.6 | 1,451 | 9,030 | 83,967 |
| Disabled | 3.8 | 203 | 24.7 | 17.1 | 22.3 | 11.3 | 24.8 | 18.4 | 6.1 | 821 | 6,724 | 67,025 |
| Adults | 3.5 | 170 | 30.5 | 5.5 | 22.5 | 13.3 | 38.3 | 18.3 | 2.1 | 559 | 622 | 7,149 |
| Children | 1.0 | 88 | 26.0 | 50.0 | 0.0 | 50.0 | 0.0 | 0.0 | 0.0 | 339 | 2 | 24 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 4.7 | 189 | 15.8 | 10.4 | 15.5 | 10.4 | 29.4 | 26.1 | 8.2 | 1,192 | 10,489 | 103,427 |
| Male | 3.4 | 164 | 15.6 | 20.1 | 21.1 | 11.2 | 25.7 | 17.5 | 4.4 | 1,051 | 5,889 | 54,738 |
| Unknown | 0.0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 4.5 | 189 | 16.0 | 11.8 | 16.8 | 11.0 | 29.1 | 24.1 | 7.2 | 1,179 | 14,842 | 142,350 |
| African American | 4.0 | 256 | 21.2 | 17.0 | 17.0 | 12.8 | 25.5 | 25.5 | 2.1 | 1,206 | 47 | 392 |
| Other/unknown | 2.3 | 98 | 12.1 | 35.2 | 24.4 | 8.0 | 17.4 | 12.4 | 2.7 | 813 | 1,489 | 15,423 |
| Use of Nursing Facilities | | | | | | | | | | | | |
| Entire year | 5.7 | 190 | 7.8 | 5.3 | 9.1 | 8.6 | 32.0 | 34.3 | 10.7 | 2,447 | 3,526 | 35,280 |
| Part year | 5.8 | 205 | 11.2 | 5.5 | 8.9 | 9.9 | 32.6 | 30.8 | 12.2 | 1,828 | 1,379 | 11,570 |
| None | 3.7 | 174 | 26.5 | 17.6 | 21.1 | 11.5 | 26.3 | 18.6 | 5.0 | 659 | 11,473 | 111,315 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 3.0 | 140 | 34.1 | 19.1 | 26.9 | 11.4 | 23.8 | 15.1 | 3.8 | 409 | 6,009 | 65,406 |
| Medically needy | 5.5 | 218 | 12.7 | 11.8 | 10.6 | 9.9 | 30.0 | 28.7 | 9.0 | 1,709 | 7,623 | 64,065 |
| Poverty related | 1.1 | 35 | 15.7 | 14.3 | 57.1 | 14.3 | 14.3 | 0.0 | 0.0 | 223 | 7 | 35 |
| Other/unknown | 4.5 | 189 | 12.1 | 8.4 | 16.4 | 11.5 | 31.9 | 24.5 | 7.3 | 1,556 | 2,739 | 28,659 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

Table 13

Dual Eligible Beneficiaries

a. Table 13 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 14
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | All Rx | | | Patented Brand-Name Drugs | | | Off-Patent Brand-Name Drugs | | | Generic Drugs | | |
|--------------------------------------|------------|--------------|-------------|---------------------------|--------------|-------------|-----------------------------|-------------|-------------|---------------|-------------|-------------|
| | No. of Rx | Rx \$ | \$ per Rx | No. of Rx | Rx \$ | \$ per Rx | No. of Rx | Rx \$ | \$ per Rx | No. of Rx | Rx \$ | \$ per Rx |
| All | 4.3 | \$180 | \$42 | 1.4 | \$104 | \$75 | 0.7 | \$35 | \$49 | 1.9 | \$32 | \$16 |
| Age | | | | | | | | | | | | |
| 5 and younger | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| 6-14 | 3.5 | 249 | 72 | 1.6 | 176 | 109 | 0.5 | 51 | 100 | 1.2 | 17 | 14 |
| 15-20 | 2.7 | 199 | 75 | 1.1 | 140 | 132 | 0.4 | 29 | 67 | 0.9 | 12 | 13 |
| 21-44 | 3.0 | 196 | 65 | 1.1 | 125 | 117 | 0.4 | 38 | 86 | 1.3 | 26 | 19 |
| 45-64 | 4.5 | 223 | 50 | 1.6 | 133 | 83 | 0.7 | 42 | 65 | 2.0 | 36 | 18 |
| 65-74 | 4.1 | 155 | 38 | 1.4 | 89 | 64 | 0.6 | 28 | 45 | 1.8 | 29 | 16 |
| 75-84 | 4.9 | 171 | 35 | 1.5 | 93 | 62 | 0.9 | 34 | 38 | 2.2 | 34 | 15 |
| 85 and older | 4.9 | 153 | 31 | 1.3 | 78 | 59 | 0.9 | 31 | 33 | 2.3 | 33 | 14 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Basis of Eligibility | | | | | | | | | | | | |
| Aged | 4.7 | 163 | 34 | 1.4 | 89 | 62 | 0.8 | 32 | 37 | 2.2 | 33 | 15 |
| Disabled | 3.8 | 203 | 54 | 1.3 | 124 | 94 | 0.5 | 39 | 71 | 1.7 | 31 | 18 |
| Adults | 3.5 | 170 | 49 | 1.2 | 102 | 84 | 0.6 | 36 | 58 | 1.5 | 25 | 17 |
| Children | 1.0 | 88 | 92 | 0.4 | 78 | 187 | 0.0 | 0 | 0 | 0.5 | 9 | 18 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Gender | | | | | | | | | | | | |
| Female | 4.7 | 189 | 40 | 1.6 | 109 | 70 | 0.8 | 35 | 46 | 2.1 | 34 | 16 |
| Male | 3.4 | 164 | 48 | 1.1 | 95 | 90 | 0.6 | 34 | 57 | 1.6 | 27 | 18 |
| Unknown | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0 |
| Race | | | | | | | | | | | | |
| White | 4.5 | 189 | 42 | 1.4 | 109 | 75 | 0.8 | 37 | 49 | 2.0 | 33 | 16 |
| African American | 4.0 | 256 | 64 | 1.2 | 156 | 129 | 0.9 | 65 | 73 | 1.8 | 30 | 17 |
| Other/unknown | 2.3 | 98 | 43 | 0.7 | 58 | 79 | 0.3 | 17 | 57 | 1.1 | 18 | 16 |
| Use of Nursing Facilities | | | | | | | | | | | | |
| Entire year | 5.7 | 190 | 33 | 1.6 | 99 | 63 | 1.1 | 40 | 37 | 2.7 | 40 | 15 |
| Part year | 5.8 | 205 | 35 | 1.7 | 114 | 65 | 1.0 | 37 | 36 | 2.7 | 41 | 15 |
| None | 3.7 | 174 | 48 | 1.3 | 105 | 81 | 0.6 | 33 | 59 | 1.6 | 28 | 17 |
| Maintenance Assistance Status | | | | | | | | | | | | |
| Cash | 3.0 | 140 | 47 | 1.1 | 84 | 80 | 0.4 | 26 | 60 | 1.4 | 23 | 17 |
| Medically needy | 5.5 | 218 | 40 | 1.7 | 122 | 72 | 1.0 | 43 | 44 | 2.5 | 40 | 16 |
| Poverty related | 1.1 | 35 | 31 | 0.4 | 26 | 71 | 0.1 | 3 | 23 | 0.5 | 4 | 7 |
| Other/unknown | 4.5 | 189 | 42 | 1.4 | 109 | 76 | 0.8 | 38 | 48 | 2.0 | 32 | 16 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table 14 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

Table 14

Dual Eligible Beneficiaries

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Montana, 5.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 15

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Therapeutic Category | No. of Rx per Bene Mo among Users | | | \$ per Bene Mo among Users | | | Total No. of Rx | | | Total Rx \$ | | | Users | | | | |
|---|-----------------------------------|------------|------------|----------------------------|------------|------------|-----------------|------------|------------|-------------|-------|------------|------------|-------------|--------------------|-----------------|------------|
| | Total | Patented | | Total | Patented | | Total | Off-Patent | Brand-Name | Generic | Total | Off-Patent | Brand-Name | Generic | As % of Dual Benes | No. of Bene Mos | |
| | | Off-Patent | Brand-Name | | Off-Patent | Brand-Name | | | | | | | | | | | Off-Patent |
| Anti-infective Agents | 0.3 | 0.2 | 0.0 | 0.2 | \$17 | \$14 | \$0 | \$2 | \$49 | \$85 | \$37 | \$12 | 31,576 | \$1,560,121 | 8,788 | 53.7 % | 92,948 |
| Biologics | 0.1 | 0.1 | 0.0 | 0.0 | 9 | 1 | 5 | 3 | 86 | 20 | 1,623 | 61 | 363 | 31,187 | 308 | 1.9 | 3,395 |
| Antineoplastic Agents | 0.7 | 0.3 | 0.1 | 0.2 | 135 | 118 | 8 | 10 | 205 | 359 | 83 | 40 | 2,913 | 596,858 | 427 | 2.6 | 4,414 |
| Endocrine/Metabolic Drugs | 1.0 | 0.5 | 0.2 | 0.4 | 26 | 19 | 3 | 4 | 26 | 41 | 17 | 11 | 67,554 | 1,733,639 | 6,536 | 39.9 | 66,884 |
| Cardiovascular Agents | 1.6 | 0.4 | 0.4 | 0.7 | 43 | 21 | 14 | 9 | 27 | 47 | 33 | 12 | 132,441 | 3,621,177 | 8,414 | 51.4 | 84,308 |
| Respiratory Agents | 0.9 | 0.5 | 0.0 | 0.4 | 35 | 24 | 1 | 10 | 39 | 52 | 34 | 24 | 52,524 | 2,035,726 | 5,585 | 34.1 | 58,731 |
| Gastrointestinal Agents | 0.7 | 0.3 | 0.2 | 0.3 | 48 | 30 | 11 | 7 | 65 | 107 | 70 | 22 | 43,363 | 2,803,834 | 5,628 | 34.4 | 58,652 |
| Genitourinary Agents | 0.5 | 0.3 | 0.0 | 0.2 | 18 | 13 | 0 | 4 | 37 | 53 | 38 | 19 | 10,382 | 380,122 | 1,991 | 12.2 | 21,074 |
| CNS Drugs | 1.3 | 0.5 | 0.2 | 0.6 | 81 | 51 | 19 | 11 | 64 | 102 | 100 | 20 | 103,729 | 6,671,743 | 8,000 | 48.8 | 82,288 |
| Stimulants/Anti-obesity/Anorexia | 0.5 | 0.1 | 0.1 | 0.3 | 25 | 9 | 6 | 10 | 51 | 83 | 51 | 37 | 1,347 | 68,927 | 255 | 1.6 | 2,732 |
| Miscellaneous Psychological/Neurological Agents | 0.5 | 0.4 | 0.0 | 0.1 | 59 | 54 | 3 | 2 | 127 | 152 | 88 | 23 | 2,677 | 340,909 | 554 | 3.4 | 5,811 |
| Analgesics and Anesthetics | 0.9 | 0.2 | 0.1 | 0.6 | 32 | 17 | 6 | 9 | 36 | 94 | 75 | 14 | 70,096 | 2,543,388 | 7,641 | 46.7 | 78,782 |
| Neuromuscular Agents | 1.0 | 0.3 | 0.2 | 0.5 | 48 | 27 | 9 | 11 | 48 | 97 | 47 | 21 | 44,379 | 2,113,467 | 4,159 | 25.4 | 44,143 |
| Nutritional Products | 0.7 | 0.0 | 0.2 | 0.5 | 14 | 2 | 5 | 7 | 19 | 48 | 29 | 14 | 26,356 | 499,993 | 3,571 | 21.8 | 36,392 |
| Hematological Agents | 0.8 | 0.1 | 0.4 | 0.3 | 25 | 9 | 11 | 5 | 33 | 185 | 25 | 18 | 17,651 | 574,965 | 2,271 | 13.9 | 22,844 |
| Topical Products | 0.4 | 0.2 | 0.1 | 0.2 | 12 | 7 | 3 | 2 | 29 | 42 | 34 | 13 | 25,061 | 716,875 | 5,698 | 34.8 | 60,877 |
| Miscellaneous Products | 0.4 | 0.2 | 0.1 | 0.1 | 87 | 42 | 39 | 7 | 196 | 256 | 260 | 50 | 3,257 | 637,349 | 681 | 4.2 | 7,295 |
| Unknown Therapeutic Category | 0.6 | 0.0 | 0.0 | 0.0 | 23 | 0 | 0 | 0 | 39 | 0 | 0 | 0 | 39,759 | 1,561,653 | 6,502 | 39.7 | 68,437 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 675,428 | 28,491,933 | n.a. | n.a. | n.a. |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

- a. Table 15 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 1999. A beneficiary who used drugs from two or more categories was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Montana, 5.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table 15

Dual Eligible Beneficiaries

TABLE 16

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Top 10 Drug Groups | Users | | | | Among Users | | |
|--------------------------------|----------------------|-------|--------------------|-----------------|-----------------------|-----------|-------------------|
| | Total Medicaid Rx \$ | No. | As % of Dual Benes | No. of Bene Mos | No. of Rx per Bene Mo | \$ per Rx | Rx \$ per Bene Mo |
| ANTIPSYCHOTICS | \$3,153,362 | 3,298 | 20.1 % | 35,660 | 0.8 | \$117 | \$88 |
| ANTIDEPRESSANTS | 2,728,200 | 6,874 | 42.0 | 72,586 | 0.7 | 54 | 38 |
| ULCER DRUGS | 2,260,446 | 5,101 | 31.1 | 54,560 | 0.5 | 77 | 41 |
| ANALGESICS - Narcotic | 1,556,059 | 8,825 | 53.9 | 92,660 | 0.5 | 33 | 17 |
| ANTICONVULSANT | 1,483,270 | 2,854 | 17.4 | 30,879 | 0.9 | 55 | 48 |
| ANTIASTHMATIC | 1,470,392 | 5,689 | 34.7 | 59,349 | 0.6 | 41 | 25 |
| ANTIHYPERTENSIVE | 1,184,539 | 4,328 | 26.4 | 44,494 | 0.7 | 36 | 27 |
| ANTIDIABETIC | 1,097,731 | 3,305 | 20.2 | 34,423 | 0.8 | 38 | 32 |
| ANALGESICS - ANTI-INFLAMMATORY | 808,220 | 3,839 | 23.4 | 41,811 | 0.4 | 47 | 19 |
| CALCIUM BLOCKERS | 731,036 | 2,114 | 12.9 | 21,812 | 0.8 | 44 | 34 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table 16 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | All Top 10 Drug Groups | | | | | ANTIPSYCHOTICS | | | | | ANTIDEPRESSANTS | | | | | | |
|-----------------------------|------------------------|---------------------|--------------|--------------------------|-----------------------------|----------------|-------------|--------------|--------------------------|-----------------------------|-----------------|-------------|--------------|--------------------------|-----------------------------|----------------|------------|
| | No. of Rx | Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 312,319 | \$16,473,255 | 3,298 | 20.1 % | 35,660 | 0.8 | \$88 | 6,874 | 42.0 % | 72,586 | 0.7 | \$38 | | | | | |
| Female | 218,757 | 11,065,134 | 1,996 | 19.0 | 21,717 | 0.7 | 75 | 4,949 | 47.2 | 52,522 | 0.7 | 37 | | | | | |
| Disabled | 80,429 | 4,730,625 | 886 | 24.7 | 9,967 | 0.8 | 103 | 2,170 | 60.6 | 23,783 | 0.6 | 38 | | | | | |
| 5 and younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 6-14 | 22 | 1,063 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 15-20 | 228 | 15,543 | 3 | 37.5 | 34 | 0.6 | 43 | 10 | 125.0 | 118 | 0.5 | 46 | | | | | |
| 21-44 | 23,442 | 1,577,652 | 399 | 33.0 | 4,461 | 0.8 | 114 | 795 | 65.8 | 8,688 | 0.6 | 38 | | | | | |
| 45-64 | 46,182 | 2,666,737 | 431 | 23.6 | 4,858 | 0.8 | 97 | 1,192 | 65.3 | 13,024 | 0.7 | 40 | | | | | |
| 65-74 | 8,846 | 399,252 | 44 | 10.4 | 510 | 0.8 | 77 | 150 | 35.5 | 1,692 | 0.6 | 31 | | | | | |
| 75-84 | 1,433 | 59,684 | 8 | 8.5 | 92 | 0.6 | 66 | 20 | 21.3 | 225 | 0.5 | 26 | | | | | |
| 85 and older | 276 | 10,694 | 1 | 4.5 | 12 | 1.0 | 6 | 3 | 13.6 | 36 | 0.9 | 65 | | | | | |
| Other Eligibles | 138,328 | 6,334,509 | 1,110 | 16.1 | 11,750 | 0.6 | 52 | 2,779 | 40.2 | 28,739 | 0.7 | 36 | | | | | |
| 5 and younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 6-14 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 15-20 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 21-44 | 2,556 | 188,958 | 39 | 24.8 | 448 | 0.7 | 69 | 53 | 33.8 | 620 | 0.9 | 64 | | | | | |
| 45-64 | 2,541 | 165,376 | 40 | 33.9 | 476 | 0.9 | 114 | 57 | 48.3 | 661 | 0.9 | 50 | | | | | |
| 65-74 | 36,881 | 1,745,492 | 243 | 13.5 | 2,557 | 0.7 | 64 | 733 | 40.7 | 7,546 | 0.7 | 33 | | | | | |
| 75-84 | 49,466 | 2,256,947 | 402 | 17.6 | 4,299 | 0.7 | 53 | 975 | 42.7 | 9,906 | 0.7 | 33 | | | | | |
| 85 and older | 46,884 | 1,977,736 | 386 | 15.2 | 3,970 | 0.5 | 35 | 961 | 37.8 | 10,006 | 0.8 | 37 | | | | | |
| Male | 93,562 | 5,408,121 | 1,302 | 22.1 | 13,943 | 0.8 | 109 | 1,925 | 32.7 | 20,064 | 0.7 | 39 | | | | | |
| Disabled | 47,661 | 3,239,392 | 758 | 24.1 | 8,137 | 0.9 | 143 | 1,067 | 34.0 | 11,362 | 0.6 | 38 | | | | | |
| 5 and younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 6-14 | 8 | 336 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 15-20 | 103 | 5,359 | 1 | 7.7 | 4 | 0.5 | 3 | 2 | 15.4 | 24 | 0.5 | 13 | | | | | |
| 21-44 | 21,416 | 1,665,551 | 461 | 30.3 | 5,037 | 0.9 | 150 | 571 | 37.5 | 6,289 | 0.6 | 39 | | | | | |
| 45-64 | 22,023 | 1,370,962 | 262 | 19.9 | 2,756 | 0.9 | 143 | 429 | 32.5 | 4,373 | 0.7 | 37 | | | | | |
| 65-74 | 3,517 | 170,433 | 22 | 9.1 | 217 | 0.9 | 38 | 50 | 20.7 | 510 | 0.7 | 42 | | | | | |
| 75-84 | 441 | 21,282 | 9 | 25.7 | 92 | 0.7 | 61 | 13 | 37.1 | 142 | 0.6 | 29 | | | | | |
| 85 and older | 153 | 5,469 | 3 | 37.5 | 31 | 0.5 | 31 | 2 | 25.0 | 24 | 0.8 | 49 | | | | | |
| Other Eligibles | 45,901 | 2,168,729 | 544 | 19.8 | 5,806 | 0.7 | 61 | 858 | 31.2 | 8,702 | 0.8 | 41 | | | | | |
| 5 and younger | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 6-14 | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 15-20 | 22 | 2,079 | 1 | 100.0 | 12 | 0.8 | 156 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |
| 21-44 | 2,807 | 222,103 | 57 | 39.6 | 682 | 0.9 | 122 | 62 | 43.1 | 709 | 0.8 | 50 | | | | | |
| 45-64 | 3,408 | 206,125 | 49 | 34.3 | 587 | 0.8 | 76 | 61 | 42.7 | 720 | 0.9 | 78 | | | | | |
| 65-74 | 13,368 | 618,376 | 132 | 15.0 | 1,448 | 0.7 | 58 | 230 | 26.1 | 2,386 | 0.7 | 31 | | | | | |
| 75-84 | 15,742 | 684,230 | 176 | 19.1 | 1,744 | 0.7 | 54 | 304 | 33.0 | 2,916 | 0.8 | 40 | | | | | |
| 85 and older | 10,554 | 435,816 | 129 | 19.7 | 1,333 | 0.6 | 33 | 201 | 30.6 | 1,971 | 0.8 | 37 | | | | | |
| Unknown | 0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | | | | | |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

- a. Table 16A includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mdmb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | ULCER DRUGS | | | | | ANALGESICS - Narcotic | | | | | ANTICONVULSANT | | | | |
|-----------------------------|--------------|--------------------------|-----------------------------|------------|-------------|-----------------------|--------------------------|-----------------------------|------------|-------------|----------------|--------------------------|-----------------------------|------------|-------------|
| | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean Rx | Mean Rx \$ |
| All | 5,101 | 31.1 % | 54,560 | 0.5 | \$41 | 8,825 | 53.9 % | 92,660 | 0.5 | \$17 | 2,854 | 17.4 % | 30,879 | 0.9 | \$48 |
| Female | 3,607 | 34.4 | 38,864 | 0.5 | 42 | 6,338 | 60.4 | 67,421 | 0.5 | 17 | 1,729 | 16.5 | 18,784 | 0.9 | 45 |
| Disabled | 1,239 | 34.6 | 13,791 | 0.4 | 39 | 2,520 | 70.4 | 27,958 | 0.5 | 16 | 944 | 26.4 | 10,409 | 0.8 | 48 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 1 | 50.0 | 11 | 0.5 | 23 | 1 | 50.0 | 10 | 0.1 | 1 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 3 | 37.5 | 34 | 1.0 | 40 | 5 | 62.5 | 60 | 0.2 | 1 | 6 | 75.0 | 70 | 1.1 | 81 |
| 21-44 | 330 | 27.3 | 3,712 | 0.4 | 35 | 862 | 71.4 | 9,610 | 0.5 | 15 | 442 | 36.6 | 4,827 | 0.8 | 54 |
| 45-64 | 720 | 39.4 | 7,902 | 0.5 | 42 | 1,332 | 72.9 | 14,649 | 0.5 | 18 | 422 | 23.1 | 4,664 | 0.9 | 46 |
| 65-74 | 157 | 37.2 | 1,815 | 0.5 | 36 | 266 | 63.0 | 3,012 | 0.5 | 12 | 61 | 14.5 | 694 | 0.7 | 24 |
| 75-84 | 27 | 28.7 | 305 | 0.4 | 34 | 48 | 51.1 | 551 | 0.4 | 9 | 11 | 11.7 | 130 | 0.6 | 23 |
| 85 and older | 1 | 4.5 | 12 | 0.4 | 32 | 6 | 27.3 | 66 | 0.2 | 3 | 2 | 9.1 | 24 | 0.6 | 46 |
| Other Eligibles | 2,368 | 34.3 | 25,073 | 0.6 | 43 | 3,818 | 55.3 | 39,463 | 0.6 | 18 | 785 | 11.4 | 8,375 | 0.9 | 40 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 30 | 19.1 | 355 | 0.6 | 47 | 47 | 29.9 | 535 | 0.3 | 5 | 71 | 45.2 | 846 | 1.1 | 95 |
| 45-64 | 27 | 22.9 | 324 | 0.6 | 41 | 30 | 25.4 | 334 | 0.2 | 2 | 46 | 39.0 | 550 | 1.1 | 65 |
| 65-74 | 619 | 34.3 | 6,681 | 0.5 | 40 | 1,057 | 58.6 | 10,924 | 0.5 | 15 | 234 | 13.0 | 2,460 | 0.8 | 40 |
| 75-84 | 822 | 36.0 | 8,698 | 0.6 | 43 | 1,233 | 53.9 | 12,803 | 0.6 | 20 | 259 | 11.3 | 2,743 | 0.8 | 29 |
| 85 and older | 870 | 34.2 | 9,015 | 0.6 | 45 | 1,451 | 57.1 | 14,867 | 0.6 | 19 | 175 | 6.9 | 1,776 | 0.9 | 25 |
| Male | 1,494 | 25.4 | 15,696 | 0.5 | 41 | 2,487 | 42.2 | 25,239 | 0.5 | 16 | 1,125 | 19.1 | 12,095 | 0.9 | 53 |
| Disabled | 707 | 22.5 | 7,672 | 0.5 | 38 | 1,441 | 45.9 | 15,129 | 0.5 | 18 | 731 | 23.3 | 7,858 | 0.9 | 57 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 1 | 50.0 | 12 | 0.1 | 17 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 1 | 7.7 | 12 | 0.1 | 2 | 2 | 15.4 | 19 | 0.2 | 1 | 4 | 30.8 | 39 | 1.4 | 86 |
| 21-44 | 311 | 20.4 | 3,389 | 0.4 | 37 | 727 | 47.7 | 7,819 | 0.4 | 15 | 400 | 26.3 | 4,419 | 0.8 | 56 |
| 45-64 | 330 | 25.0 | 3,597 | 0.5 | 40 | 595 | 45.1 | 6,103 | 0.5 | 20 | 304 | 23.0 | 3,170 | 1.0 | 59 |
| 65-74 | 57 | 23.6 | 600 | 0.5 | 32 | 106 | 43.8 | 1,083 | 0.5 | 21 | 21 | 8.7 | 206 | 1.0 | 50 |
| 75-84 | 5 | 14.3 | 38 | 0.9 | 95 | 10 | 28.6 | 93 | 0.2 | 5 | 1 | 2.9 | 12 | 1.0 | 80 |
| 85 and older | 2 | 25.0 | 24 | 1.0 | 41 | 1 | 12.5 | 12 | 0.1 | 1 | 1 | 12.5 | 12 | 0.8 | 7 |
| Other Eligibles | 787 | 28.6 | 8,024 | 0.6 | 44 | 1,046 | 38.1 | 10,110 | 0.5 | 14 | 394 | 14.3 | 4,237 | 0.9 | 46 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 100.0 | 12 | 1.0 | 18 |
| 21-44 | 26 | 18.1 | 299 | 0.5 | 41 | 43 | 29.9 | 424 | 0.4 | 12 | 83 | 57.6 | 957 | 1.0 | 78 |
| 45-64 | 47 | 32.9 | 552 | 0.9 | 50 | 32 | 22.4 | 376 | 0.2 | 3 | 74 | 51.7 | 874 | 1.1 | 54 |
| 65-74 | 230 | 26.1 | 2,397 | 0.5 | 38 | 307 | 34.8 | 3,121 | 0.5 | 15 | 94 | 10.7 | 1,016 | 0.9 | 40 |
| 75-84 | 268 | 29.1 | 2,674 | 0.6 | 46 | 379 | 41.2 | 3,479 | 0.6 | 15 | 97 | 10.5 | 944 | 0.8 | 25 |
| 85 and older | 216 | 32.9 | 2,102 | 0.7 | 47 | 285 | 43.4 | 2,710 | 0.5 | 13 | 45 | 6.9 | 434 | 0.9 | 24 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Dual Eligible Beneficiaries

Table 16B

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table 16B includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | ANTI-ASTHMATIC | | | | | ANTI-HYPERTENSIVE | | | | | ANTI-DIABETIC | | | | |
|-----------------------------|----------------|--------------------------|-----------------------------|----------------|-------------|-------------------|--------------------------|-----------------------------|----------------|-------------|---------------|--------------------------|-----------------------------|----------------|-------------|
| | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ |
| All | 5,689 | 34.7 % | 59,349 | 0.6 | \$25 | 4,328 | 26.4 % | 44,494 | 0.7 | \$27 | 3,305 | 20.2 % | 34,423 | 0.8 | \$32 |
| Female | 3,999 | 38.1 | 42,282 | 0.6 | 25 | 3,035 | 28.9 | 31,463 | 0.8 | 27 | 2,372 | 22.6 | 25,055 | 0.8 | 33 |
| Disabled | 1,455 | 40.6 | 15,898 | 0.6 | 23 | 767 | 21.4 | 8,419 | 0.7 | 24 | 761 | 21.2 | 8,408 | 0.8 | 37 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 25.0 | 24 | 0.7 | 23 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 314 | 26.0 | 3,527 | 0.4 | 15 | 103 | 8.5 | 1,140 | 0.7 | 22 | 95 | 7.9 | 1,087 | 0.9 | 36 |
| 45-64 | 893 | 48.9 | 9,707 | 0.6 | 27 | 474 | 26.0 | 5,143 | 0.7 | 25 | 510 | 27.9 | 5,547 | 0.8 | 40 |
| 65-74 | 206 | 48.8 | 2,196 | 0.6 | 24 | 154 | 36.5 | 1,758 | 0.6 | 24 | 129 | 30.6 | 1,460 | 0.8 | 31 |
| 75-84 | 34 | 36.2 | 384 | 0.5 | 16 | 28 | 29.8 | 291 | 0.8 | 32 | 15 | 16.0 | 180 | 0.8 | 31 |
| 85 and older | 8 | 36.4 | 84 | 0.6 | 26 | 6 | 27.3 | 63 | 0.7 | 17 | 12 | 54.5 | 134 | 0.5 | 12 |
| Other Eligibles | 2,544 | 36.8 | 26,384 | 0.6 | 26 | 2,268 | 32.8 | 23,044 | 0.8 | 28 | 1,611 | 23.3 | 16,647 | 0.8 | 30 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 18 | 11.5 | 209 | 0.2 | 15 | 8 | 5.1 | 94 | 0.8 | 32 | 12 | 7.6 | 143 | 1.1 | 56 |
| 45-64 | 18 | 15.3 | 201 | 0.6 | 24 | 23 | 19.5 | 274 | 0.8 | 27 | 21 | 17.8 | 252 | 0.8 | 41 |
| 65-74 | 881 | 48.9 | 9,170 | 0.6 | 26 | 577 | 32.0 | 5,851 | 0.7 | 29 | 509 | 28.2 | 5,264 | 0.8 | 33 |
| 75-84 | 917 | 40.1 | 9,464 | 0.7 | 29 | 844 | 36.9 | 8,620 | 0.8 | 28 | 646 | 28.3 | 6,705 | 0.9 | 32 |
| 85 and older | 710 | 27.9 | 7,340 | 0.5 | 22 | 816 | 32.1 | 8,205 | 0.8 | 27 | 423 | 16.6 | 4,283 | 0.8 | 23 |
| Male | 1,690 | 28.7 | 17,067 | 0.6 | 25 | 1,293 | 22.0 | 13,031 | 0.7 | 26 | 933 | 15.8 | 9,368 | 0.8 | 30 |
| Disabled | 652 | 20.8 | 6,811 | 0.6 | 22 | 559 | 17.8 | 5,839 | 0.7 | 24 | 423 | 13.5 | 4,435 | 0.8 | 32 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 50.0 | 12 | 0.2 | 2 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 4 | 30.8 | 48 | 0.3 | 7 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 199 | 13.1 | 2,163 | 0.5 | 17 | 158 | 10.4 | 1,732 | 0.6 | 20 | 128 | 8.4 | 1,366 | 0.9 | 33 |
| 45-64 | 348 | 26.4 | 3,525 | 0.6 | 24 | 327 | 24.8 | 3,330 | 0.7 | 25 | 240 | 18.2 | 2,487 | 0.8 | 33 |
| 65-74 | 100 | 41.3 | 1,063 | 0.7 | 28 | 60 | 24.8 | 615 | 0.7 | 26 | 44 | 18.2 | 450 | 0.9 | 33 |
| 75-84 | 5 | 14.3 | 60 | 0.6 | 16 | 7 | 20.0 | 78 | 0.8 | 37 | 6 | 17.1 | 72 | 0.9 | 27 |
| 85 and older | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 25.0 | 24 | 0.9 | 26 | 5 | 62.5 | 60 | 0.5 | 15 |
| Other Eligibles | 1,038 | 37.8 | 10,256 | 0.7 | 26 | 734 | 26.7 | 7,192 | 0.8 | 28 | 510 | 18.6 | 4,933 | 0.9 | 28 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |
| 21-44 | 13 | 9.0 | 146 | 0.4 | 20 | 10 | 6.9 | 111 | 0.8 | 19 | 3 | 2.1 | 36 | 1.6 | 112 |
| 45-64 | 22 | 15.4 | 260 | 0.7 | 29 | 25 | 17.5 | 299 | 0.9 | 31 | 15 | 10.5 | 179 | 0.8 | 33 |
| 65-74 | 319 | 36.2 | 3,256 | 0.7 | 30 | 241 | 27.3 | 2,429 | 0.8 | 28 | 193 | 21.9 | 1,948 | 0.8 | 29 |
| 75-84 | 398 | 43.3 | 3,790 | 0.7 | 26 | 287 | 31.2 | 2,685 | 0.8 | 28 | 182 | 19.8 | 1,639 | 0.9 | 27 |
| 85 and older | 286 | 43.6 | 2,804 | 0.6 | 22 | 171 | 26.1 | 1,668 | 0.8 | 28 | 117 | 17.8 | 1,131 | 0.9 | 25 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table 16C includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 16D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BOE, AND AGE^{a, b, c}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | ANALGESICS - ANTI-INFLAMMATORY | | | | CALCIUM BLOCKERS | | | | | | | |
|-----------------------------|--------------------------------|--------------------------|-----------------------------|----------------|------------------|--------------|--------------------------|-----------------------------|----------------|-------------|---------------|-----------------|
| | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Users | Users as % of Dual Benes | No. of Bene Mos among Users | Mean No. of Rx | Mean Rx \$ | No. of Benes | No. of Bene Mos |
| All | 3,839 | 23.4 % | 41,811 | 0.4 | \$19 | 2,114 | 12.9 % | 21,812 | 0.8 | \$34 | 16,378 | 158,165 |
| Female | 2,784 | 26.5 | 30,495 | 0.4 | 20 | 1,580 | 15.1 | 16,474 | 0.8 | 34 | 10,489 | 103,427 |
| Disabled | 1,168 | 32.6 | 13,104 | 0.4 | 21 | 388 | 10.8 | 4,238 | 0.7 | 32 | 3,582 | 36,857 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 2 | 100.0 | 21 | 0.8 | 39 | 2 | 21 |
| 15-20 | 2 | 25.0 | 24 | 0.2 | 2 | 1 | 12.5 | 12 | 0.9 | 76 | 8 | 94 |
| 21-44 | 349 | 28.9 | 3,923 | 0.3 | 17 | 62 | 5.1 | 693 | 0.7 | 33 | 1,208 | 12,613 |
| 45-64 | 662 | 36.3 | 7,372 | 0.4 | 25 | 232 | 12.7 | 2,477 | 0.7 | 32 | 1,826 | 18,272 |
| 65-74 | 124 | 29.4 | 1,436 | 0.4 | 17 | 69 | 16.4 | 785 | 0.7 | 32 | 422 | 4,573 |
| 75-84 | 27 | 28.7 | 303 | 0.3 | 12 | 17 | 18.1 | 190 | 0.8 | 26 | 94 | 1,048 |
| 85 and older | 4 | 18.2 | 46 | 0.1 | 4 | 5 | 22.7 | 60 | 0.6 | 25 | 22 | 236 |
| Other Eligibles | 1,616 | 23.4 | 17,391 | 0.4 | 20 | 1,192 | 17.3 | 12,236 | 0.8 | 34 | 6,907 | 66,570 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 21-44 | 25 | 15.9 | 295 | 0.3 | 13 | 5 | 3.2 | 60 | 0.6 | 12 | 157 | 1,761 |
| 45-64 | 19 | 16.1 | 228 | 0.4 | 17 | 7 | 5.9 | 82 | 0.9 | 34 | 118 | 1,392 |
| 65-74 | 533 | 29.6 | 5,724 | 0.4 | 22 | 294 | 16.3 | 3,004 | 0.7 | 33 | 1,803 | 16,912 |
| 75-84 | 520 | 22.7 | 5,553 | 0.4 | 19 | 440 | 19.2 | 4,550 | 0.8 | 36 | 2,286 | 21,914 |
| 85 and older | 519 | 20.4 | 5,591 | 0.5 | 18 | 446 | 17.5 | 4,540 | 0.8 | 34 | 2,543 | 24,591 |
| Male | 1,055 | 17.9 | 11,316 | 0.4 | 16 | 534 | 9.1 | 5,338 | 0.7 | 33 | 5,889 | 54,738 |
| Disabled | 601 | 19.1 | 6,534 | 0.3 | 18 | 235 | 7.5 | 2,418 | 0.7 | 35 | 3,142 | 30,168 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 50.0 | 12 | 0.4 | 9 | 2 | 24 |
| 15-20 | 2 | 15.4 | 23 | 0.1 | 1 | 2 | 15.4 | 24 | 0.6 | 53 | 13 | 130 |
| 21-44 | 279 | 18.3 | 3,117 | 0.3 | 11 | 72 | 4.7 | 752 | 0.6 | 33 | 1,523 | 15,537 |
| 45-64 | 276 | 20.9 | 2,873 | 0.4 | 22 | 128 | 9.7 | 1,292 | 0.8 | 36 | 1,319 | 11,787 |
| 65-74 | 38 | 15.7 | 449 | 0.4 | 41 | 26 | 10.7 | 269 | 0.8 | 37 | 242 | 2,264 |
| 75-84 | 4 | 11.4 | 48 | 0.2 | 1 | 5 | 14.3 | 57 | 0.8 | 12 | 35 | 335 |
| 85 and older | 2 | 25.0 | 24 | 0.8 | 13 | 1 | 12.5 | 12 | 1.2 | 38 | 8 | 91 |
| Other Eligibles | 454 | 16.5 | 4,782 | 0.4 | 15 | 299 | 10.9 | 2,920 | 0.8 | 32 | 2,747 | 24,570 |
| 5 and younger | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |
| 6-14 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 |
| 15-20 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 1 | 12 |
| 21-44 | 21 | 14.6 | 244 | 0.3 | 6 | 4 | 2.8 | 40 | 0.8 | 35 | 144 | 1,633 |
| 45-64 | 26 | 18.2 | 304 | 0.5 | 11 | 7 | 4.9 | 84 | 0.8 | 47 | 143 | 1,665 |
| 65-74 | 153 | 17.3 | 1,615 | 0.4 | 15 | 101 | 11.5 | 1,018 | 0.8 | 34 | 882 | 7,871 |
| 75-84 | 142 | 15.4 | 1,461 | 0.5 | 15 | 122 | 13.3 | 1,171 | 0.8 | 31 | 920 | 7,659 |
| 85 and older | 112 | 17.1 | 1,158 | 0.5 | 16 | 65 | 9.9 | 607 | 0.8 | 30 | 656 | 5,718 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0.0 | 0 | 0.0 | 0 | 0 | 0 |

Table 16D

Dual Eligible Beneficiaries

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

- a. Table 16D includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 1999. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 1999. For information about these drug groups, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE 17
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | Rx \$ per Bene Mo | No. of Rx per Bene Mo | No. of All-Year NF Residents | Bene Mos among All-Year NF Residents |
|-----------------------------|-------------------|-----------------------|------------------------------|--------------------------------------|
| All | \$190 | 5.7 | 3,526 | 35,280 |
| Age | | | | |
| 0-64 | 285 | 6.5 | 218 | 2,403 |
| 65-74 | 221 | 6.0 | 377 | 3,829 |
| 75-84 | 212 | 6.1 | 1,086 | 10,601 |
| 85 and older | 159 | 5.2 | 1,845 | 18,447 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Gender | | | | |
| Female | 188 | 5.7 | 2,557 | 26,069 |
| Male | 197 | 5.6 | 969 | 9,211 |
| Unknown | 0 | 0.0 | 0 | 0 |
| Race | | | | |
| White | 193 | 5.8 | 3,358 | 33,572 |
| African American | 219 | 7.3 | 10 | 88 |
| Other/unknown | 130 | 3.8 | 158 | 1,620 |
| Basis of Eligibility | | | | |
| Aged | 183 | 5.6 | 3,233 | 32,057 |
| Disabled | 261 | 6.3 | 291 | 3,199 |
| Adults | 143 | 5.5 | 2 | 24 |
| Children | 0 | 0.0 | 0 | 0 |
| Unknown | 0 | 0.0 | 0 | 0 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table 17 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their 1999 Medicaid enrollment. A total of 1,379 beneficiaries who were in nursing facilities for part of their enrollment and their 11,570 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE 18

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Therapeutic Category | No. of Rx per Bene Mo among Users | | | \$ per Bene Mo among Users | | | Total # of Rx | | | Total Rx \$ | | | Users | | | | |
|---|-----------------------------------|------------|------------|----------------------------|------------|------------|---------------|------------|------------|-------------|------------|------------|---------|------------------------------------|-----------------|--------|--------|
| | Total | Patented | Off-Patent | Total | Patented | Off-Patent | Total | Patented | Off-Patent | Total | Patented | Off-Patent | No. | As % of Dual All-Year NF Residents | No. of Bene Mos | | |
| | | Brand-Name | Generic | | Brand-Name | Generic | | Brand-Name | Generic | | Brand-Name | Generic | | | | | |
| Anti-infective Agents | 0.3 | 0.2 | 0.0 | 0.1 | \$12 | \$10 | \$0 | \$1 | \$37 | \$63 | \$23 | \$10 | 8,250 | 2,351 | \$308,562 | 66.7 % | 25,292 |
| Biologicals | 0.1 | 0.0 | 0.0 | 0.1 | 2 | 1 | 0 | 2 | 26 | 19 | 0 | 31 | 198 | 194 | 5,052 | 5.5 | 2,096 |
| Antineoplastic Agents | 0.8 | 0.4 | 0.1 | 0.3 | 150 | 134 | 7 | 9 | 186 | 325 | 53 | 35 | 692 | 82 | 128,373 | 2.3 | 854 |
| Endocrine/Metabolic Drugs | 1.2 | 0.4 | 0.2 | 0.5 | 25 | 16 | 3 | 6 | 21 | 37 | 13 | 11 | 18,016 | 1,459 | 375,416 | 41.4 | 15,172 |
| Cardiovascular Agents | 1.8 | 0.3 | 0.5 | 0.9 | 38 | 13 | 15 | 10 | 21 | 38 | 28 | 11 | 41,968 | 2,267 | 880,689 | 64.3 | 23,184 |
| Respiratory Agents | 0.9 | 0.4 | 0.0 | 0.5 | 33 | 18 | 1 | 14 | 37 | 49 | 34 | 28 | 12,533 | 1,298 | 458,038 | 36.8 | 13,788 |
| Gastrointestinal Agents | 1.0 | 0.3 | 0.3 | 0.4 | 50 | 25 | 17 | 9 | 53 | 90 | 65 | 21 | 14,575 | 1,451 | 770,911 | 41.2 | 15,304 |
| Genitourinary Agents | 0.6 | 0.3 | 0.0 | 0.3 | 21 | 16 | 1 | 5 | 36 | 53 | 40 | 18 | 3,795 | 592 | 136,741 | 16.8 | 6,361 |
| CNS Drugs | 1.3 | 0.6 | 0.2 | 0.5 | 68 | 47 | 13 | 8 | 52 | 76 | 77 | 15 | 27,651 | 2,028 | 1,434,855 | 57.5 | 21,171 |
| Stimulants/Anti-obesity/Anorexia | 0.9 | 0.0 | 0.2 | 0.6 | 18 | 1 | 6 | 11 | 20 | 42 | 28 | 17 | 304 | 30 | 6,130 | 0.9 | 337 |
| Miscellaneous Psychological/Neurological Agents | 0.8 | 0.7 | 0.0 | 0.0 | 93 | 91 | 1 | 1 | 118 | 125 | 70 | 20 | 1,114 | 137 | 131,041 | 3.9 | 1,410 |
| Analgesics and Anesthetics | 1.0 | 0.2 | 0.1 | 0.7 | 32 | 19 | 3 | 9 | 32 | 80 | 48 | 13 | 18,584 | 1,743 | 588,028 | 49.4 | 18,292 |
| Neuromuscular Agents | 1.1 | 0.2 | 0.3 | 0.6 | 46 | 18 | 16 | 13 | 41 | 74 | 52 | 22 | 10,464 | 873 | 432,956 | 24.8 | 9,341 |
| Nutritional Products | 0.9 | 0.0 | 0.2 | 0.6 | 14 | 0 | 5 | 9 | 16 | 13 | 23 | 14 | 11,954 | 1,264 | 193,279 | 35.8 | 13,346 |
| Hematological Agents | 1.0 | 0.1 | 0.6 | 0.4 | 26 | 8 | 12 | 6 | 25 | 147 | 20 | 17 | 7,541 | 698 | 189,773 | 19.8 | 7,255 |
| Topical Products | 0.5 | 0.2 | 0.1 | 0.2 | 13 | 7 | 4 | 3 | 27 | 39 | 35 | 13 | 9,171 | 1,755 | 250,533 | 49.8 | 18,975 |
| Miscellaneous Products | 0.1 | 0.0 | 0.0 | 0.1 | 5 | 2 | 2 | 2 | 39 | 60 | 98 | 20 | 399 | 253 | 15,366 | 7.2 | 2,812 |
| Unknown Therapeutic Category | 0.7 | 0.0 | 0.0 | 0.0 | 21 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 13,386 | 1,791 | 401,100 | 50.8 | 19,207 |
| TOTAL NO. OF RX AND RX \$ | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | 200,595 | n.a. | 6,706,843 | n.a. | n.a. |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

- a. Table 18 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 1999. A total of 1,379 beneficiaries who were in nursing facilities for part of their enrollment and their 11,570 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 1999. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003).
- e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.Medi-Span.com/products/product_mddb.asp (May 13 2003). In Montana, 5.9 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.3
 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | No. of Benes | | | | | No. of Bene Mos | | | | | |
|--------------------------------------|---------------|--------------|--------------|------------|----------|-----------------|---------------|---------------|--------------|-----------|----------|
| | All | Aged | Disabled | Adults | Children | All | Aged | Disabled | Adults | Children | Unknown |
| All | 16,386 | 9,031 | 6,725 | 628 | 2 | 158,318 | 83,973 | 67,081 | 7,240 | 24 | 0 |
| Age | | | | | | | | | | | |
| 5 and younger | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-14 | 5 | 0 | 4 | 0 | 1 | 57 | 0 | 45 | 0 | 12 | 0 |
| 15-20 | 22 | 0 | 21 | 0 | 1 | 238 | 0 | 226 | 0 | 12 | 0 |
| 21-44 | 3,038 | 5 | 2,732 | 301 | 0 | 31,653 | 60 | 28,192 | 3,401 | 0 | 0 |
| 45-64 | 3,407 | 8 | 3,145 | 254 | 0 | 33,152 | 96 | 30,071 | 2,985 | 0 | 0 |
| 65-74 | 3,350 | 2,641 | 664 | 45 | 0 | 31,626 | 24,271 | 6,837 | 518 | 0 | 0 |
| 75-84 | 3,335 | 3,184 | 129 | 22 | 0 | 30,956 | 29,309 | 1,383 | 264 | 0 | 0 |
| 85 and older | 3,229 | 3,193 | 30 | 6 | 0 | 30,636 | 30,237 | 327 | 72 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gender | | | | | | | | | | | |
| Female | 10,495 | 6,615 | 3,583 | 297 | 0 | 103,513 | 63,217 | 36,892 | 3,404 | 0 | 0 |
| Male | 5,891 | 2,416 | 3,142 | 331 | 2 | 54,805 | 20,756 | 30,189 | 3,836 | 24 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race | | | | | | | | | | | |
| White | 14,847 | 8,342 | 5,932 | 572 | 1 | 142,473 | 77,060 | 58,779 | 6,622 | 12 | 0 |
| African American | 48 | 20 | 27 | 1 | 0 | 404 | 187 | 205 | 12 | 0 | 0 |
| Other/unknown | 1,491 | 669 | 766 | 55 | 1 | 15,441 | 6,726 | 8,097 | 606 | 12 | 0 |
| Use of Nursing Facilities | | | | | | | | | | | |
| All year | 3,526 | 3,233 | 291 | 2 | 0 | 35,280 | 32,057 | 3,199 | 24 | 0 | 0 |
| Part year | 1,379 | 1,205 | 162 | 12 | 0 | 11,570 | 9,907 | 1,522 | 141 | 0 | 0 |
| None | 11,481 | 4,593 | 6,272 | 614 | 2 | 111,468 | 42,009 | 62,360 | 7,075 | 24 | 0 |
| Maintenance Assistance Status | | | | | | | | | | | |
| Cash | 6,015 | 1,943 | 4,045 | 26 | 1 | 65,522 | 21,458 | 43,783 | 269 | 12 | 0 |
| Medically needy | 7,623 | 5,663 | 1,960 | 0 | 0 | 64,068 | 48,427 | 15,641 | 0 | 0 | 0 |
| Poverty related | 7 | 0 | 0 | 7 | 0 | 35 | 0 | 0 | 35 | 0 | 0 |
| Other/unknown | 2,741 | 1,425 | 720 | 595 | 1 | 28,693 | 14,088 | 7,657 | 6,936 | 12 | 0 |
| Dual Status^c | | | | | | | | | | | |
| Full dual, all year | 16,386 | 9,031 | 6,725 | 628 | 2 | 158,318 | 83,973 | 67,081 | 7,240 | 24 | 0 |
| Full dual, part year | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Managed Care Status | | | | | | | | | | | |
| FFS all year | 16,359 | 9,030 | 6,713 | 614 | 2 | 158,040 | 83,967 | 66,943 | 7,106 | 24 | 0 |
| FFS part year, with Rx claims | 17 | 0 | 10 | 7 | 0 | 179 | 0 | 114 | 65 | 0 | 0 |
| FFS part year, no Rx claims | 2 | 0 | 1 | 1 | 0 | 20 | 0 | 12 | 8 | 0 | 0 |
| MC all year, with Rx claims | 8 | 1 | 1 | 6 | 0 | 79 | 6 | 12 | 61 | 0 | 0 |
| MC all year, no Rx claims | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

a. Table A.3 includes the beneficiaries represented by Cell F of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid pharmacy benefits during all months of Medicaid enrollment in 1999. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.4
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS
 DUAL ELIGIBLE BENEFICIARIES, MONTANA, 1999

| Beneficiary Characteristics | Bene(s) and | | | |
|----------------------------------|---|---|---|---|
| | Bene Mo(s) in Cell F of Table 1 No. of Bene(s) | Bene Mo(s) in Cell G of Table 1 No. of Bene(s) | Bene Mo(s) in Cell H of Table 1 No. of Bene(s) | Bene Mo(s) in Cell I of Table 1 No. of Bene(s) |
| All | 16,386 | 158,318 | 16,378 | 158,165 |
| FFS all year | 16,359 | 158,040 | 16,359 | 158,040 |
| FFS part year, with Rx claims | 17 | 179 | 17 | 119 |
| FFS part year, with no Rx claims | 2 | 20 | 2 | 6 |
| MC all year, with Rx claims | 8 | 79 | 0 | 0 |
| MC all year, with no Rx claims | 0 | 0 | 0 | 0 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 06/25/2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

SUPPLEMENTAL TABLE 1
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES^{a, b}
 MONTANA, 1999

Total Number of Dual Eligible Beneficiaries 16,378
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries \$28,491,933
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary \$1,740

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|-------------------------------|------------------------|---|
| \$0 | 2,277 | 13.9 % | \$0 | 0.0 % |
| 1-500 | 4,117 | 25.1 | 841,426 | 3.0 |
| 501-1,000 | 2,198 | 13.4 | 1,622,712 | 5.7 |
| 1,001-1,500 | 1,676 | 10.2 | 2,075,199 | 7.3 |
| 1,501-2,000 | 1,257 | 7.7 | 2,196,437 | 7.7 |
| 2,001-2,500 | 1,017 | 6.2 | 2,278,222 | 8.0 |
| 2,501-3,000 | 791 | 4.8 | 2,169,969 | 7.6 |
| 3,001-3,500 | 625 | 3.8 | 2,027,955 | 7.1 |
| 3,501-4,000 | 444 | 2.7 | 1,663,874 | 5.8 |
| 4,001-4,500 | 375 | 2.3 | 1,591,897 | 5.6 |
| 4,501-5,000 | 300 | 1.8 | 1,420,021 | 5.0 |
| 5,001-5,500 | 242 | 1.5 | 1,271,320 | 4.5 |
| 5,501-6,000 | 193 | 1.2 | 1,107,652 | 3.9 |
| 6,001-6,500 | 141 | 0.9 | 878,154 | 3.1 |
| 6,501-7,000 | 121 | 0.7 | 813,382 | 2.9 |
| 7,001-7,500 | 91 | 0.6 | 657,104 | 2.3 |
| 7,501-8,000 | 70 | 0.4 | 540,811 | 1.9 |
| 8,001-8,500 | 48 | 0.3 | 396,887 | 1.4 |
| 8,501-9,000 | 51 | 0.3 | 445,693 | 1.6 |
| 9,001-9,500 | 44 | 0.3 | 406,218 | 1.4 |
| 9,501-10,000 | 37 | 0.2 | 362,625 | 1.3 |
| 10,001+ | 263 | 1.6 | 3,724,375 | 13.1 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 10/26/2004.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 1999.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1A
 MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65^{a, b, c}
 MONTANA, 1999

Total Number of Disabled Dual Eligible Beneficiaries, Age < 65 5,901
 Total Pharmacy Reimbursement for Disabled Dual Eligible Beneficiaries, Age < 65 \$12,499,542
 Mean Pharmacy Reimbursement per Disabled Dual Eligible Beneficiary, Age < 65 \$2,118

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age < 65 | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|---|------------------------|---|
| \$0 | 960 | 16.3% | 0 | 0.0% |
| 1-500 | 1,559 | 26.4 | 286,394 | 2.3 |
| 501-1,000 | 636 | 10.8 | 470,664 | 3.8 |
| 1,001-1,500 | 486 | 8.2 | 598,366 | 4.8 |
| 1,501-2,000 | 383 | 6.5 | 665,660 | 5.3 |
| 2,001-2,500 | 294 | 5.0 | 656,976 | 5.3 |
| 2,501-3,000 | 229 | 3.9 | 630,775 | 5.0 |
| 3,001-3,500 | 204 | 3.5 | 664,622 | 5.3 |
| 3,501-4,000 | 158 | 2.7 | 593,108 | 4.7 |
| 4,001-4,500 | 145 | 2.5 | 617,412 | 4.9 |
| 4,501-5,000 | 120 | 2.0 | 570,015 | 4.6 |
| 5,001-5,500 | 84 | 1.4 | 441,883 | 3.5 |
| 5,501-6,000 | 90 | 1.5 | 517,927 | 4.1 |
| 6,001-6,500 | 53 | 0.9 | 331,036 | 2.6 |
| 6,501-7,000 | 64 | 1.1 | 430,786 | 3.4 |
| 7,001-7,500 | 48 | 0.8 | 345,963 | 2.8 |
| 7,501-8,000 | 41 | 0.7 | 317,532 | 2.5 |
| 8,001-8,500 | 33 | 0.6 | 272,480 | 2.2 |
| 8,501-9,000 | 33 | 0.6 | 288,446 | 2.3 |
| 9,001-9,500 | 31 | 0.5 | 285,891 | 2.3 |
| 9,501-10,000 | 28 | 0.5 | 274,105 | 2.2 |
| 10,001+ | 222 | 3.8 | 3,239,501 | 25.9 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 10/26/2004.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 1999.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

c. This table is limited to dual eligible beneficiaries who were under age 65 and also indicated as disabled in the MAX files. Therefore, dual eligible beneficiaries under age 65 in "adults" or "children" basis-of-eligibility categories in Table 12 are excluded because they were not classified as disabled in the MAX files. Disabled dual eligible beneficiaries age 65 and over are included in Supplemental Tables 1B through 1D, depending on their age.

SUPPLEMENTAL TABLE 1B
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74^{a, b}
 MONTANA, 1999

Total Number of Dual Eligible Beneficiaries, Age 65-74 3,349
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65-74 \$4,907,799
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65-74 \$1,466

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 65-74 | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|--|------------------------|---|
| \$0 | 667 | 19.9 % | 0 | 0.0 |
| 1-500 | 794 | 23.7 | 162,007 | 3.3 |
| 501-1,000 | 446 | 13.3 | 327,200 | 6.7 |
| 1,001-1,500 | 318 | 9.5 | 393,629 | 8.0 |
| 1,501-2,000 | 228 | 6.8 | 398,951 | 8.1 |
| 2,001-2,500 | 191 | 5.7 | 430,329 | 8.8 |
| 2,501-3,000 | 155 | 4.6 | 424,643 | 8.7 |
| 3,001-3,500 | 120 | 3.6 | 386,443 | 7.9 |
| 3,501-4,000 | 88 | 2.6 | 327,976 | 6.7 |
| 4,001-4,500 | 66 | 2.0 | 279,517 | 5.7 |
| 4,501-5,000 | 55 | 1.6 | 259,136 | 5.3 |
| 5,001-5,500 | 64 | 1.9 | 336,993 | 6.9 |
| 5,501-6,000 | 32 | 1.0 | 183,704 | 3.7 |
| 6,001-6,500 | 30 | 0.9 | 186,106 | 3.8 |
| 6,501-7,000 | 23 | 0.7 | 154,286 | 3.1 |
| 7,001-7,500 | 17 | 0.5 | 122,944 | 2.5 |
| 7,501-8,000 | 11 | 0.3 | 84,445 | 1.7 |
| 8,001-8,500 | 6 | 0.2 | 49,382 | 1.0 |
| 8,501-9,000 | 9 | 0.3 | 78,242 | 1.6 |
| 9,001-9,500 | 4 | 0.1 | 36,907 | 0.8 |
| 9,501-10,000 | 2 | 0.1 | 19,787 | 0.4 |
| 10,001+ | 23 | 0.7 | 265,172 | 5.4 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 10/26/2004.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 1999.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

—
icy
ent
%

SUPPLEMENTAL TABLE 1C

MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84^{a, b}
MONTANA, 1999

Total Number of Dual Eligible Beneficiaries, Age 75-84 3,335
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 75-84 \$5,288,175
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 75-84 \$1,586

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 75-84 | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|--|------------------------|---|
| \$0 | 394 | 11.8 % | 0 | 0.0 % |
| 1-500 | 799 | 24.0 | 173,411 | 3.3 |
| 501-1,000 | 480 | 14.4 | 356,372 | 6.7 |
| 1,001-1,500 | 388 | 11.6 | 486,137 | 9.2 |
| 1,501-2,000 | 263 | 7.9 | 460,010 | 8.7 |
| 2,001-2,500 | 242 | 7.3 | 543,286 | 10.3 |
| 2,501-3,000 | 193 | 5.8 | 527,338 | 10.0 |
| 3,001-3,500 | 147 | 4.4 | 477,962 | 9.0 |
| 3,501-4,000 | 88 | 2.6 | 328,757 | 6.2 |
| 4,001-4,500 | 82 | 2.5 | 346,662 | 6.6 |
| 4,501-5,000 | 70 | 2.1 | 331,419 | 6.3 |
| 5,001-5,500 | 52 | 1.6 | 271,755 | 5.1 |
| 5,501-6,000 | 37 | 1.1 | 211,810 | 4.0 |
| 6,001-6,500 | 28 | 0.8 | 173,655 | 3.3 |
| 6,501-7,000 | 18 | 0.5 | 120,145 | 2.3 |
| 7,001-7,500 | 16 | 0.5 | 115,500 | 2.2 |
| 7,501-8,000 | 12 | 0.4 | 92,875 | 1.8 |
| 8,001-8,500 | 5 | 0.1 | 41,571 | 0.8 |
| 8,501-9,000 | 5 | 0.1 | 43,519 | 0.8 |
| 9,001-9,500 | 3 | 0.1 | 27,830 | 0.5 |
| 9,501-10,000 | 3 | 0.1 | 29,298 | 0.6 |
| 10,001+ | 10 | 0.3 | 128,863 | 2.4 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 10/26/2004.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 1999.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1D
 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER^{a, b}
 MONTANA, 1999

Total Number of Dual Eligible Beneficiaries, Age 85+ 3,229
 Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 85+ \$4,675,736
 Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 85+ \$1,448

| Annual Pharmacy Reimbursement per Beneficiary | Number of Beneficiaries | Percent of Dual Beneficiaries, Age 85+ | Pharmacy Reimbursement | Percent of Total Pharmacy Reimbursement |
|---|-------------------------|--|------------------------|---|
| \$0 | 223 | 6.9 % | 0 | 0.0 % |
| 1-500 | 812 | 25.1 | 189,084 | 4.0 |
| 501-1,000 | 571 | 17.7 | 420,942 | 9.0 |
| 1,001-1,500 | 431 | 13.3 | 530,511 | 11.3 |
| 1,501-2,000 | 342 | 10.6 | 600,567 | 12.8 |
| 2,001-2,500 | 244 | 7.6 | 545,836 | 11.7 |
| 2,501-3,000 | 176 | 5.5 | 481,780 | 10.3 |
| 3,001-3,500 | 127 | 3.9 | 409,611 | 8.8 |
| 3,501-4,000 | 91 | 2.8 | 342,341 | 7.3 |
| 4,001-4,500 | 63 | 2.0 | 266,761 | 5.7 |
| 4,501-5,000 | 45 | 1.4 | 212,439 | 4.5 |
| 5,001-5,500 | 30 | 0.9 | 156,981 | 3.4 |
| 5,501-6,000 | 24 | 0.7 | 137,085 | 2.9 |
| 6,001-6,500 | 19 | 0.6 | 118,839 | 2.5 |
| 6,501-7,000 | 8 | 0.2 | 54,569 | 1.2 |
| 7,001-7,500 | 4 | 0.1 | 29,023 | 0.6 |
| 7,501-8,000 | 4 | 0.1 | 30,832 | 0.7 |
| 8,001-8,500 | 3 | 0.1 | 24,963 | 0.5 |
| 8,501-9,000 | 3 | 0.1 | 26,553 | 0.6 |
| 9,001-9,500 | 3 | 0.1 | 27,673 | 0.6 |
| 9,501-10,000 | 1 | 0.0 | 9,915 | 0.2 |
| 10,001+ | 5 | 0.2 | 59,431 | 1.3 |

Source: Data for this table are from the MAX 1999 file for Montana, released by CMS in 12/2003. This table was produced on 10/26/2004.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 1999.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.